Proteomics flags US rollout of kidney test at global diabetes summit
The launch took place at the American Diabetes Association's 85th scientific sessions talkfest in Chicago. The annual conference marks the world's largest gathering of diabetes experts, making it the ideal stage to unveil PromarkerD to the US market.
PromarkerD is a simple predictive blood test capable of identifying a person's risk of developing diabetic kidney disease (DKD) up to four years before symptoms appear, offering a potential lifeline to the more than 32 million Americans living with type 2 diabetes.
According to clinical studies, the patented test accurately predicted kidney function decline in up to 86 per cent of patients who otherwise showed no symptoms.
'This marks a significant milestone in our global commercialisation strategy.'
Proteomics International managing director Dr Richard Lipscombe
More than half of all adults with diabetes in the US will develop kidney complications. These cases contribute to a colossal US$130 billion in annual healthcare costs - more than a quarter of the nation's Medicare budget.
Proteomics International managing director Dr Richard Lipscombe said: 'We're excited to introduce PromarkerD to the US at such a prestigious event. This marks a significant milestone in our global commercialisation strategy and underscores our commitment to addressing the diabetes epidemic through precision medicine.'
The PromarkerD rollout will begin in California, supported by the company's recently commissioned CLIA-certified testing laboratory in Irvine. US patients will be able to access the test from Proteomics International's integrated digital health platform. The sales model was piloted in Australia and designed to support direct-to-consumer and clinical engagement.
Renowned diabetes professional Davida Kruger, from Henry Ford Health in Detroit, called the test 'a paradigm shift in diabetes care.' Kruger noted early identification of at-risk patients means doctors can use preventive strategies long before irreversible damage occurs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
AU Financial Review
a day ago
- AU Financial Review
Pro Medicus runs to $300 so fast investors can't catch up
The ASX's No.1 rocket, Pro Medicus, keeps making its way to the moon. On signing two contracts worth a combined $190 million over the coming decade, the healthcare imaging software group added nearly $3 billion of market value.
The Age
a day ago
- The Age
Protoemics diabetes test gets important US health insurance nod
Proteomics International is on the verge of releasing its groundbreaking PromarkerD diabetes-related blood test across the United States, a milestone step ahead the device's international commercialisation. PromarkerD has just been assigned an American Medical Association PLA billing code, required for doctors to order the test and for facilities to bill for its use. From October 1, patients and healthcare providers will be able to submit claims for the test to be reimbursed by their health insurers – an essential step towards a broader market uptake. PromarkerD was designed to meet an area of unmet need by identifying diabetic patients at risk of developing kidney disease four years before any symptoms appear. According to the company's latest clinical study, its patented next-generation PromarkerD test accurately predicted kidney function decline in up to 86 per cent of patients who otherwise showed no symptoms, replicating the results from earlier clinical trials. 'Ensuring kidney health is a priority for our company and obtaining this dedicated PLA code is a crucial milestone in our strategy to improve access to meaningful diagnostic tests.' Proteomics International managing director Dr Richard Lipscombe Catching early signs of diabetic kidney disease means patients can receive preventive care well before they develop costly and life-threatening end-stage kidney disease, avoiding the need for dialysis or a kidney transplant. The simple finger-prick blood test could potentially throw a lifeline to more than 32 million Americans living with type 2 diabetes, given more than half of all adults with diabetes in the US will develop kidney complications. These cases contribute to a colossal US$130 billion in annual healthcare costs - more than a quarter of the nation's Medicare budget. Proteomics International managing director Dr Richard Lipscombe said: 'Ensuring kidney health is a priority for our company and obtaining this dedicated PLA code is a crucial milestone in our strategy to improve access to meaningful diagnostic tests. Expanding access to PromarkerD will help to improve kidney health for patients everywhere.' The PLA code is widely used across America's complex health insurance system to report the use of medical procedures and services. It also allows insurers to monitor their use.
Sydney Morning Herald
a day ago
- Sydney Morning Herald
Protoemics diabetes test gets important US health insurance nod
Proteomics International is on the verge of releasing its groundbreaking PromarkerD diabetes-related blood test across the United States, a milestone step ahead the device's international commercialisation. PromarkerD has just been assigned an American Medical Association PLA billing code, required for doctors to order the test and for facilities to bill for its use. From October 1, patients and healthcare providers will be able to submit claims for the test to be reimbursed by their health insurers – an essential step towards a broader market uptake. PromarkerD was designed to meet an area of unmet need by identifying diabetic patients at risk of developing kidney disease four years before any symptoms appear. According to the company's latest clinical study, its patented next-generation PromarkerD test accurately predicted kidney function decline in up to 86 per cent of patients who otherwise showed no symptoms, replicating the results from earlier clinical trials. 'Ensuring kidney health is a priority for our company and obtaining this dedicated PLA code is a crucial milestone in our strategy to improve access to meaningful diagnostic tests.' Proteomics International managing director Dr Richard Lipscombe Catching early signs of diabetic kidney disease means patients can receive preventive care well before they develop costly and life-threatening end-stage kidney disease, avoiding the need for dialysis or a kidney transplant. The simple finger-prick blood test could potentially throw a lifeline to more than 32 million Americans living with type 2 diabetes, given more than half of all adults with diabetes in the US will develop kidney complications. These cases contribute to a colossal US$130 billion in annual healthcare costs - more than a quarter of the nation's Medicare budget. Proteomics International managing director Dr Richard Lipscombe said: 'Ensuring kidney health is a priority for our company and obtaining this dedicated PLA code is a crucial milestone in our strategy to improve access to meaningful diagnostic tests. Expanding access to PromarkerD will help to improve kidney health for patients everywhere.' The PLA code is widely used across America's complex health insurance system to report the use of medical procedures and services. It also allows insurers to monitor their use.
